Purpose: To determine practices and opinions among study investigators in the Zoster Eye Disease Study (ZEDS) regarding suppressive valacyclovir treatment for recent-onset and chronic herpes zoster ophthalmicus (HZO).
H erpes zoster ophthalmicus (HZO) is caused by localized reactivation of the varicella zoster virus (VZV) in the ophthalmic division of cranial nerve V. Herpes zoster infections have serious complications including an acute unilateral painful rash, postherpetic neuralgia (a severely debilitating chronic pain syndrome), acute and chronic eye disease, and potentially fatal strokes. Recent studies using polymerase chain reaction testing have shown that some complications of HZO, including dendriform epithelial keratitis and iritis, are associated with chronic and/or recurrent active VZV infection. [1] [2] [3] [4] [5] [6] Dendriform lesions respond to topical and systemic antiviral treatment. 6, 7 In addition, corneas removed from patients with HZO during transplantation have been found by polymerase chain reaction to have specific VZV genomic DNA sequences up to 51 years after the HZO onset. 8 Furthermore, the Acyclovir Prevention Trial of the Herpetic Eye Disease Study determined that prolonged suppressive antiviral treatment significantly reduced recurrent eye disease caused by herpes simplex virus (HSV), a different herpes virus, and was most beneficial in stromal keratitis, a disease manifestation considered to be immune mediated with the role of active viral infection unknown. 9 This treatment is now standard care and has improved outcomes in HSV eye disease. Given the evidence that active VZV infection contributes to complications of HZO and that suppressive antiviral treatment is effective in HSV eye disease, which has similarities to HZO, it is important to determine whether suppressive antiviral treatment is effective in HZO.
Although corneal specialists routinely manage recurrent and chronic cases of HZO, there is much variability in the use of antivirals. In addition, there is no evidence from a prospective clinical trial regarding the efficacy of prolonged antiviral therapy to reduce chronic and/or recurrent disease. The Zoster Eye Disease Study (ZEDS), funded by the National Eye Institute (NEI) of the National Institutes of Health, is a randomized controlled clinical trial that seeks to determine whether prolonged suppressive valacyclovir treatment with 1000 mg orally daily for 1 year reduces complications of HZO, including eye disease and/or postherpetic neuralgia, compared with the placebo. Over 200 investigators/ophthalmologists at 60 participating clinical centers in the United States are participating in ZEDS.
Currently, antiviral treatment for 7 to 10 days for acute herpes zoster (HZ), including HZO, is supported by randomized controlled trials and approved by the Food and Drug Administration, but there are no established or evidence-based guidelines for the use of suppressive oral antiviral treatment in chronic and/or recurrent HZO. 10 Despite this lack of evidence, many corneal specialists use this treatment. As reported in a previous survey of 100 corneal specialists conducted in 2010 in preparation for ZEDS, approximately 30% of Kera-net listserv respondents used prolonged antiviral treatment. 11 A second Kera-net survey done in preparation for this study identified potential study investigators and preferred antiviral treatment. 12 The purpose of the current survey is to determine the baseline practice patterns and opinions of ZEDS investigators at the beginning of study participant enrollment.
METHODS
To gain an understanding of the current antiviral treatment being prescribed by the ZEDS trial principal investigators and coinvestigators, a Qualtrics Internet-based survey (Provo, UT) was distributed to 170 ZEDS study investigators who had completed participating center applications as of November 1, 2017. This survey was opened in December 2017, with reminders sent for 4 weeks, and closed in January 2018. All responses were anonymous. To ensure a sufficiently representative response while maintaining the privacy of the decision to participate, individual reminders were sent to nonrespondents by a person outside the ZEDS organization (confidential fielding of the survey with anonymous storage of the responses). This study was approved by the Institutional Review Board at the New York University School of Medicine.
The survey consisted of 15 questions and was divided into 2 sections (See Supplemental Digital Content 1, http:// links.lww.com/ICO/A710). The first section provided 2 clinical vignettes to assess current practices regarding antiviral use for treatment of stromal keratitis in recent-onset HZO, defined as within 6 months, and chronic HZO. Specifically, respondents were asked about treatment regimens regarding topical steroids and/or oral antivirals, preferred antiviral drug and dosage, duration of antiviral treatment, and to comment on their antiviral protocol.
The second section assessed respondents' opinions regarding whether prolonged suppressive antiviral treatment could prevent or reduce recurrent and/or chronic HZO during and/or after the period of administration. Lastly, general demographic information was gathered, including years in practice, practice setting (community/private vs. academic/ university vs. other), practice location, number of HZO cases treated in the past year, and percentage of cases treated in the past year with chronic/recurrent HZO.
Statistical analyses using the Fisher exact test (for categorical variables) and the analysis of variance test (for continuous variables) were used to compare consistency of opinions and practices between related questions, and to compare opinions and treatment practices between subgroups of clinicians, including practice setting, location, specialty, and years of practice. Analyses were conducted in R Language and Environment for Statistical Computing program version 3.3.2 (Vienna, Austria). The results of this survey were also compared with those of the 2010 Kera-net survey.
RESULTS

Demographics
The survey was sent to 170 ZEDS study investigators. The survey response rate was 72.4% (123/170). Of these respondents, 69.9% (86/123) practiced in an academic/ university setting, 26.0% (32/123) practiced in a community or private setting, and 4.1% (5/123) answered that they practiced in other settings (Table 1) . This is similar to the demographics of all ZEDS investigators in that 68.8% (117/ 170) practiced in academic settings, compared with 31.2% (53/170) who were in community or private practices (P = 0.51, Table 1 ).
Current Practice Patterns
In our clinical vignette assessing the antiviral use for treatment of stromal keratitis in recent-onset HZO, the majority of respondents chose to treat with topical steroids and high-dose antivirals (45.5%, 56/123) or low-dose antivirals (23.6%, 29/123) ( Table 2) . A minority of respondents chose to treat with topical steroids alone (24.4%, 30/123). These results were similar to practice patterns for treatment of chronic HZO, with the majority of respondents using topical steroids and high-dose antivirals (39.0%, 48/123) or low dose antivirals (24.4%, 30/123) (P = 0.86) ( Table 2 ). Valacyclovir 1000 mg was the preferred antiviral for both recent-onset (61.8%, 76/123) and chronic HZO (63.4%, 78/123). Responses for the preferred duration of treatment were also similar between recent-onset and chronic HZO (P = 0.58). In recent-onset and chronic HZO, 50.4% and 52.8% (62/123 and 65/123) of respondents, respectively, used prolonged antiviral treatment for as long as steroids were employed, for 1 year, or for longer than 1 year. Only 11.4% and 12.2% (14/123 and 15/123) of respondents did not prescribe antivirals for recentonset and chronic HZO, respectively.
Treatment practice patterns did not vary between academic versus community/private practice settings (P = 0.94) or geographic regions for both recent-onset (P = 0.69) and chronic HZO (P = 0.47) (Table 3) . However, the number of years in practice was associated with a significant variation in treatment (Table 3 , P ,0.001). Respondents who used topical steroids were in practice an average of 22 years compared with respondents who used topical steroids and high-or low-dose antivirals, who were in practice an average of 13 and 16 years, respectively. Self-reported percentages of chronic HZO cases treated in the community (33.7%) and academic settings (32.2%) were similar (P = 0.78).
In response to an optional open-ended question asking respondents to describe their antiviral protocol, most frequent comments described using initial high dose antivirals followed by a taper to chronic low dose antivirals for both recent-onset and chronic HZO. For recent-onset HZO, respondents (N = 20) chose to prescribe high-dose antivirals for 1 to 2 weeks followed by low-dose antivirals for 1 year. For chronic HZO, there was a longer duration of antiviral treatment with respondents (N = 18) using high-dose antivirals until resolution of disease, followed by long-term or indefinite low-dose antiviral prophylaxis.
Current Opinions and Attitudes on Prolonged Antiviral Prophylaxis
When questioned whether they believed that prolonged antiviral prophylaxis could prevent or reduce recurrent and/or chronic signs of HZO during the period of administration, 70.7% (87/123) of respondents said yes, 5.7% (7/123) said no, and 23.6% (29/123) did not know (Table 4) . However, when asked whether prolonged suppressive antiviral 
Comparison of the Current Survey With 2010 Kera-Net Survey
The results of this study were compared with those of our previous study in 2010, in which 100 corneal specialists responded to a survey sent to subscribers of the Cornea Society Kera-net listserv conducted in preparation for the ZEDS trial (Table 4) . 11 The majority of Kera-net respondents were community-based ophthalmologists (69.4%, 68/ 98), in contrast to the current survey of ZEDS investigators, in which the majority of respondents practice in an academic/university setting (69.9%, 86/123, P , 0.001, Table 1 ). In our current survey, ZEDS investigators see a higher volume of patients with HZO, with 59.0% (72/122) treating 20 or more cases per year compared with the previous survey, in which only 4.8% (4/84) treated 20 or more cases in the past year (P , 0.001, Table 4 ). The demographics of the study population of the 2 surveys differ significantly, limiting comparisons that can be made between the responses in the 2 surveys.
DISCUSSION
Overall, the results of this survey demonstrate that a majority (70.7%, 87/123, Table 4 ) of ZEDS investigators believe that antivirals are efficacious and can reduce complications of HZO during their period of administration. Approximately half of the respondents treat recent-onset and chronic HZO with prolonged antivirals in addition to topical steroids. The length of antiviral treatment is significantly longer (P = 0.008) among ZEDS investigators who responded to this survey compared with Kera-net subscribers who responded to the 2010 survey ( Table 4 ). The demographics of ZEDS investigators are different from those of the Kera-net listerv, in which a majority of respondents were community or private practice-based ophthalmologists who treated a relatively small number of patients with HZO. This difference may account for the different practice patterns and attitudes. However, in our current survey, there was no significant difference in treatment practices regarding the use of topical steroids and antivirals for treatment of stromal keratitis due to HZO between the community and academic settings.
It is unclear why practice patterns and attitudes with regard to aniviral treatment of HZO are different between ZEDS investigators in 2017 and Kera-net respondents in 2010. The demographics of the 2 study populations vary significantly, so one cannot conclude whether there has been a shift in practice patterns and attitudes. This study population of ZEDS investigators may be a self-selected group: they may either already believe that suppressive antiviral treatment is effective, or after being involved in the study, which has been planned since 2010, now believe that it will work. In addition, a recent retrospective study in Italy published in 2014 found that low-dose suppressive valacyclovir (500 mg once daily) or acyclovir (400 mg twice daily) decreased recurrent episodes of inflammation by 35% in patients with HZO (and 39% in patients with HSV). This study may have also provided some early evidence of the potential efficacy of suppressive antiviral treatment that may have changed some practice patterns. 13 In addition, another recent publication in 2016 on the epidemiology of recurrent and chronic HZO discussed the importance of studying the role of suppressive antiviral treatment in reducing disease. 14 Despite the frequent use of prolonged suppressive antiviral treatment in HZO, it is currently not evidence based. The ZEDS randomized placebo controlled clinical trial of prolonged suppressive valacyclovir treatment is a unique opportunity to obtain evidence to determine standard of care *Other includes responses in which antivirals alone were used. †n = 246 is the sum of responses for both recent-onset and chronic HZO in the current survey, which was combined to compare with the 2010 survey. There was no statistical difference between responses for recent and chronic HZO in the current survey (P = 0.62).
in treatment of HZO to reduce complications and improve outcomes. We encourage participation in this important clinical trial by enrolling your patients with HZO who are eligible. Information regarding ZEDS is available on the Web site https://med.nyu.edu/research/zoster-eye-diseasestudy/zoster-eye-disease-study.
